Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,430
datasets available to search
ShareScore release 0.9.0
Dataset results
3,430 results for “PD”
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
ClinicalTrials.gov study NCT00735267. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression
ClinicalTrials.gov study NCT06939452. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants
ClinicalTrials.gov study NCT07186946. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
ClinicalTrials.gov study NCT02676869. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687
ClinicalTrials.gov study NCT01217905. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT05338775. IPD Sharing: YES. Countries: 4. Publications: 0.
A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
ClinicalTrials.gov study NCT04821687. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients
ClinicalTrials.gov study NCT03029858. IPD Sharing: NO. Countries: 1. Publications: 0.
Famotidine for Levodopa-induced Dyskinesia in PD
ClinicalTrials.gov study NCT01937078. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia
ClinicalTrials.gov study NCT01327859. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
ClinicalTrials.gov study NCT06955156. IPD Sharing: NO. Countries: 1. Publications: 0.
A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
ClinicalTrials.gov study NCT01550484. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies
ClinicalTrials.gov study NCT03746704. IPD Sharing: YES. Countries: 1. Publications: 0.
VC/VS for Apathy in PD
ClinicalTrials.gov study NCT06991335. IPD Sharing: YES. Countries: 1. Publications: 0.
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity
ClinicalTrials.gov study NCT05897008. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negat
ClinicalTrials.gov study NCT05852691. IPD Sharing: YES. Countries: 16. Publications: 0.
MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT
ClinicalTrials.gov study NCT02528682. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia
ClinicalTrials.gov study NCT02439203. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
ClinicalTrials.gov study NCT06325683. IPD Sharing: YES. Countries: 1. Publications: 0.
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
ClinicalTrials.gov study NCT04514081. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.